Rifampicin

Generic Name: Rifampicin

Brand Names: Isonarif, Rifadin, Rifamate, Rifater, Rofact

Drug Type: Small Molecule

Chemical Formula: C_₄₃H_₅₈N_₄O_₁₂

CAS Number: 13292-46-1

Unique Ingredient Identifier: VJT6J7R4TR

Background: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)

Indication: Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.

Associated Conditions: Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis

Associated Therapies: Antibacterial therapy

Clinical Trials

CYP2C9 Activity Evaluated With a Simple Finger Prick

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: flurbiprofen
Drug: flurbiprofen, rifampicin
Drug: flurbiprofen + fluconazole

First Posted Date: 2009-12-04

Last Posted Date: 2011-01-11

Lead Sponsor: University Hospital, Geneva

Target Recruit Count: 10

Registration Number: NCT01026714

Locations: 🇨🇭
University Hospitals, Geneva 14, Switzerland

Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)

Phase 1

Completed

Conditions: Lymphoma, Large-Cell, Anaplastic
Disease, Hodgkin
Neoplasms
Carcinomas
Lymphoma, Non-Hodgkin

Interventions: Drug: ketoconazole
Drug: brentuximab vedotin
Drug: rifampin
Drug: midazolam

First Posted Date: 2009-12-04

Last Posted Date: 2014-12-18

Lead Sponsor: Seagen Inc.

Target Recruit Count: 73

Registration Number: NCT01026415

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
Karmanos Cancer Institute / Wayne State University, Detroit, Michigan, United States
🇺🇸
St. Francis Medical Group Oncology & Hematology Specialists, Indianapolis, Indiana, United States

and more 3 locations

Study of VX-770 and Rifampin in Healthy Male Subjects

Phase 1

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: VX-770
Drug: Rifampin

First Posted Date: 2009-11-23

Last Posted Date: 2010-05-10

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 24

Registration Number: NCT01018368

Drug-Drug Interaction Study With Rifampin

Phase 1

Completed

Conditions: Alzheimer Disease

Interventions: Drug: BMS-708163
Drug: Rifampin

First Posted Date: 2009-10-27

Last Posted Date: 2011-01-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 20

Registration Number: NCT01002079

Locations: 🇮🇳
Local Institution, Bangalore, India

Pregnane X Receptor (PXR) Agonist Rifampicin Effects on Glucose, Lipid and Hormone Homeostasis

Phase 4

Completed

Conditions: Glucose Tolerance

Interventions: Drug: Placebo
Drug: Rifampicin

First Posted Date: 2009-09-28

Last Posted Date: 2011-02-10

Lead Sponsor: University of Oulu

Target Recruit Count: 12

Registration Number: NCT00985270

Locations: 🇫🇮
Oulu University Hospital, Oulu, Finland

Validation Study of Multiple Probe Compounds for Drug Interaction Evaluation

Phase 1

Completed

Conditions: Drug Interactions

Interventions: Drug: Caffeine
Drug: Ketoconazole
Drug: Rosiglitazone
Drug: Fluconazole
Drug: Flurbiprofen
Drug: Rifampin
Drug: Omeprazole
Drug: Dextromethorphan
Drug: Midazolam
Drug: Rosuvastatin

First Posted Date: 2009-08-24

Last Posted Date: 2018-01-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 87

Registration Number: NCT00964106

Locations: 🇰🇷
GSK Investigational Site, Seoul, Korea, Republic of

Pharmacokinetic Study for Anti-tuberculosis Drugs

Not Applicable

Conditions: Pulmonary Tuberculosis

Interventions: Drug: Rifater and EMB

First Posted Date: 2009-07-29

Last Posted Date: 2011-04-12

Lead Sponsor: Taipei Medical University WanFang Hospital

Target Recruit Count: 16

Registration Number: NCT00948077

Locations: 🇨🇳
Taipei Medical University- Wan Fang Hospital, Taipei, Taiwan

A Study to Evaluate the Effect of Ketoconazole and Rifampicin on the Pharmacokinetics of Fimasartan in Healthy Male Volunteers

Phase 1

Completed

Conditions: Essential Hypertension

Interventions: Drug: Fimasartan, Ketoconazole, Rifampicin

First Posted Date: 2009-07-13

Last Posted Date: 2009-10-08

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 24

Registration Number: NCT00938262

Randomized Clinical Trial Comparing 4RIF vs. 9INH for LTBI Treatment-effectiveness

Phase 3

Completed

Conditions: Latent Tuberculosis Infection

Interventions: Drug: Isoniazid
Drug: Rifampin

First Posted Date: 2009-07-02

Last Posted Date: 2017-12-19

Lead Sponsor: McGill University

Target Recruit Count: 6031

Registration Number: NCT00931736

Locations: 🇦🇺
Woolcock Institute of Medical Research, Sydney, New South Wales, Australia
🇬🇭
Research and Development Unit, Komfo Anokye Teaching Hospital, Kumasi, Ghana
🇬🇳
Service de Phtisiologie, Hopital National Ignace Deen, Conakry, Guinea

and more 9 locations

Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications

Phase 1

Completed

Conditions: Opioid Dependency
HIV Infections

Interventions: Drug: Fosamprenavir/Ritonavir
Drug: Darunavir/Ritonavir
Drug: Rifabutin
Drug: Rifampin
Drug: Buprenorphine

First Posted Date: 2009-04-08

Last Posted Date: 2014-05-06

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 63

Registration Number: NCT00877591

Locations: 🇺🇸
San Francisco General Hospital, San Francisco, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy